Why this AIM stock is one to consider buying now

This AIM stock is backed by a profitable, growing business but it’s also making decent advances in the North American market.

| More on:
Person holding magnifying glass over important document, reading the small print

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One FTSE AIM stock I’ve been watching has a fast-growing business and does more trade abroad than it does in the UK.

Earnings have been increasing at pace. But the icing on the cake is the foothold the business has in the North American market.

If momentum builds in the US over the coming months and years, it’s possible the stock could perform well from where it is now.

Strong potential for growth ahead

The business is already well-established, profitable and expanding like mad. Just how I like it, with jam today and the potential for cases of the stuff in the future!

It’s Tristel (LSE: TSTL), the global infection prevention company that makes and supplies products using its proprietary chlorine dioxide (ClO2) chemistry.

The firm’s products go to hospitals, and around 87% of sales come from its Tristel brand for the decontamination of medical devices. Another top seller is its Cache brand for the sporicidal disinfection of environmental surfaces, which delivers about 8% of total sales.

There’s been wide acceptance of the company’s offering and that shows in the multi-year trading figures. Double-digit percentage annual increases in earnings have become normal. City analysts predict more ahead for the current trading year to June 2025 with an uplift of about 20%.

Today’s (21 October) full-year report for the year to June 2024 is robust and “ahead of expectations“. The directors also included an upbeat outlook statement. That’s not surprising because the business is making big strides abroad.

Overseas sales and modest profits

For example, today’s figures show the firm earned more revenue from overseas than it did in the UK. Just under 48% of revenue came from the UK with the rest from foreign markets.

However, those UK sales delivered around 86% of profit before tax, much of it from the firm’s largest customer, the NHS. That outcome suggests selling products to places like Australia, Germany and the rest of the world may involve bigger costs. It’s also possible profit margins are lower.

So one risk here is the company’s focus on international expansion may not prove to be as lucrative as hoped. For example, the US market is a well-known graveyard for the hopes and dreams of many previous UK companies. Tesco is one that tried and failed to conquer the market.

Tristel said today it has encountered “more purchasing bureaucracy” in the US than anticipated. So it’s taking longer than expected for some customers to adopt the products. However, “momentum is growing” across the pond, and the American healthcare market is the world’s largest.

I think the setbacks and uncertainty reflect in the share price chart.

However, the weakness has sharpened up the valuation somewhat. With the stock near 388p, the forward-looking price-to-earnings (P/E) rating for the current trading year is just below 25. That’s still a growth rating, but not wildly excessive.

The US market is just one international region in which the company is making progress. So, on balance and despite the risks, I’d conduct deeper research now with a view to possibly picking up a few of the shares to hold long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended Tesco Plc and Tristel Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After a 13.5% drop, is the Lloyds share price a bargain?

Uncertainty over car loan liabilities has sent the Lloyds share price tumbling. But as the situation develops, when does the…

Read more »

Investing Articles

Up 84% this year! Can Rolls-Royce shares just keep on flying?

After a stunning 2023, Rolls-Royce shares have had an excellent 2024 so far. Our writer thinks the price may rise…

Read more »

Growth Shares

3 wide-moat FTSE 100 stocks that offer value today

These FTSE 100 companies have some of the widest economic moats in the index. And right now, Edward Sheldon believes…

Read more »

Investing Articles

Yielding 10.6% after a 20% decline, are abrdn shares simply too cheap to ignore?

Buying a falling knife can be a risky strategy, but Andrew Mackie believes the abrdn share price decline might be…

Read more »

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £994 a month

A Warren Buffett investment from 1994 returns 60% each year in dividends. With enough time, could Stephen Wright achieve a…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

If I’d put £20,000 into a FTSE 100 tracker a year ago, here’s what I’d have now

The FTSE 100 is having a great year so far this year, and it seems overdue. What's the best way…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

BP share price decline is presenting a gift for value investors

As the BP share price decline accelerates following disappointing earnings, this Fool’s long-term bullish stance has not changed.

Read more »

Investing Articles

1 S&P 500 company from my ‘best stocks to buy now’ list

Zaven Boyrazian explains why this cheap-looking S&P 500 growth enterprise is on his ‘best stocks to buy now’ list for…

Read more »